Evidence map›Paper›PMID 38162907›Full record

ArticleBrain communications2024

Association of cardiovascular disease management drugs with Lewy body dementia: a case-control study.

Sonja W Scholz, Brian E Moroz, Sara Saez-Atienzar, Ruth Chia, Elizabeth K Cahoon, Clifton L Dalgard, American Genome Center, International Lewy Body Dementia Genomics Consortium, Daryl Michal Freedman, Ruth M Pfeiffer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Abnormal Cerebrovascular Activity, Perfusion, and Glymphatic Clearance in Lewy Body Diseases.Movement disorders : official journal of the Movement Disorder Society · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Sonja W ScholzDepartment of Neurology, Johns Hopkins University Medical Center, Baltimore, MD 21287, USA.ORCID https://orcid.org/0000-0002-6623-0429
Brian E MorozBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Sara Saez-AtienzarLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20814, USA.
Ruth ChiaLaboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD 20814, USA.ORCID https://orcid.org/0000-0002-4709-7423
Elizabeth K CahoonBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Clifton L DalgardDepartment of Anatomy, Physiology and Genetics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA.
American Genome Center
International Lewy Body Dementia Genomics Consortium
Daryl Michal FreedmanBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Ruth M PfeifferBiostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
National Institutes of Health · USUniformed Services University of the Health Sciences · US

Funding

Research Education Core FP30AG072977 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI SANDRA WEINTRAUB · 2021 to 2026
$26.3M
Genetic characterization of atypical parkinsonismZIANS003154 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI SCHOLZ, SONJA · 2016 to 2025
$15.4M
nvestigating the role of neuroinflammation in Limbic-predominant age related TDP43 encephalopathyK08AG065463 · NIA · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI FLANAGAN, MARGARET E · 2020 to 2024
$816k
Intramural NIH HHS ZIA NS003154NIA NIH HHS K08 AG065463NIA NIH HHS P30 AG072977
6 · The paper itself

Abstract

Lewy body dementia is the second most common neurodegenerative dementia after Alzheimer's disease. Disease-modifying therapies for this disabling neuropsychiatric condition are critically needed. To identify drugs associated with the risk of developing Lewy body dementia, we performed a population-based case-control study of 148 170 US Medicare participants diagnosed with Lewy body dementia between 1 January 2008 and 31 December 2014 and of 1 253 043 frequency-matched controls. We estimated odds ratios and 95% confidence intervals for the association of Lewy body dementia risk with 1017 prescription drugs overall and separately for the three major racial groups (Black, Hispanic and White Americans). We identified significantly reduced Lewy body dementia risk associated with drugs used to treat cardiovascular diseases (anti-hypertensives: odds ratio = 0.72, 95% confidence interval = 0.70-0.74,

Indexed as

cardiovascular diseasegenomic analysisLewy body dementiaMedicareprescription drugs

Identifiers

PMID38162907
PMCPMC10754316
OpenAlexW4389925862

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.